BYT Launches NCIB Amid AGM Results to Strengthen Corporate Outlook
Vancouver, British Columbia — December 2, 2025 — BYT Holdings Ltd. announced its plan to initiate a Normal Course...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Vancouver, British Columbia — December 2, 2025 — BYT Holdings Ltd. announced its plan to initiate a Normal Course...
